CRISPR approach could limit toxicity of CAR-T therapy in AML – Drug Target Review
Drug Target Review |
CRISPR approach could limit toxicity of CAR-T therapy in AML
Drug Target Review A new approach may provide a new path towards treating acute myeloid leukaemia (AML) with CAR-T cells. To treat AML, investigators have to target a specific protein – CD33 – that's also expressed on healthy cells, meaning the therapy cannot attack the … |
